BioNTech SE (BNTX) reports strong revenue growth and pipeline progress, while navigating financial and legal hurdles.

In a report released today, Cory Kasimov from Evercore ISI maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target of $110.00. The company’s shares closed yesterday at ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...

Operator Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz ...

Q3 2024 Earnings Call Transcript November 4, 2024 Operator: Welcome to BioNTech’s Third Quarter 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor ...

BioNTech SE (BNTX) has released an update. BioNTech SE reported a strong third quarter in 2024, with revenues reaching €1.2 ...

BioNTech (NASDAQ:BNTX – Get Free Report) will be announcing its earnings results before the market opens on Monday, November ...

German biotech BioNTech saw its shares rise more than 3% to $114.98 pre-market today, as it reported financial results for the three months ended September 30, 2024, that beat expectations. Revenues ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In the trading week from November 4th to 8th, experts opinion is between volatile to bearish in Dow Jones, S&P 500, and ...